Aversa, T.
De Sanctis, L.
Faienza, M. F.
Gambineri, A.
Balducci, A.
D’Aprile, R.
Di Somma, C.
Giavoli, C.
Grossi, A.
Meriggiola, M. C.
Profka, E.
Salerno, M.
Stagi, S.
Scarano, E.
Zatelli, M. C.
Wasniewska, M. http://orcid.org/0000-0002-8299-2677
Funding for this research was provided by:
Sandoz
Article History
Received: 4 October 2023
Accepted: 11 January 2024
First Online: 20 February 2024
Declarations
:
: Tommaso Aversa has consulted for Pfizer and Sandoz. Anna Balducci, Roberta D’Aprile, Carolina Di Somma, Maria Felicia Faienza, Alessandra Gambineri, Claudia Giavoli, Armando Grossi, Maria Cristina Meriggiola, Eriselda Profka, Mariacarolina Salerno, and Maria Chiara Zatelli have consulted for Sandoz. Stefano Stagi has consulted for Aboca, Novonordisk, and Sandoz. Malgorzata Wasniewska is a consultant for Merck, Novonordisk, Pfizer, and Sandoz. Emanuela Scarano has consulted for Alexion, Biomarin, Novonordisk, Pfizer, and Sandoz. Luisa De Sanctis has no interests to declare.
: Not applicable.
: Not applicable.
: The study does not involve human participants and/or animals.